Brewin Dolphin Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$39K	Hold	250	–	–	﹤0.01%	204
2022 Q1	$39K	Buy	+250	New	+$36.3K	﹤0.01%	208
2021 Q3	–	Sell	-14	Closed	-$2.49K	–	337
2021 Q2	$2.49K	Buy	+14	New	+$2.42K	﹤0.01%	326

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Brewin Dolphin Wealth Management's JAZZ Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2022 at 250 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #204.

Brewin Dolphin Wealth Management first reported a position in JAZZ in Q2 2021 and has held it in 3 quarters since. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

Brewin Dolphin Wealth Management held 250 shares of Jazz Pharmaceuticals worth $39K as of Q2 2022.
Brewin Dolphin Wealth Management left its Jazz Pharmaceuticals share count unchanged in Q2 2022.
Jazz Pharmaceuticals made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #204 holding.
Brewin Dolphin Wealth Management first reported a position in Jazz Pharmaceuticals in Q2 2021 and has held it in 3 quarters since.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.